PE20211776A1 - Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer - Google Patents

Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer

Info

Publication number
PE20211776A1
PE20211776A1 PE2021000726A PE2021000726A PE20211776A1 PE 20211776 A1 PE20211776 A1 PE 20211776A1 PE 2021000726 A PE2021000726 A PE 2021000726A PE 2021000726 A PE2021000726 A PE 2021000726A PE 20211776 A1 PE20211776 A1 PE 20211776A1
Authority
PE
Peru
Prior art keywords
octan
triazol
alzheimer
dihydro
gamma
Prior art date
Application number
PE2021000726A
Other languages
English (en)
Inventor
Beat Frei
Hasane Ratni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20211776A1 publication Critical patent/PE20211776A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de formula (I) donde R 1 es halogeno; m es 1,2 o 3; n es 1, 2, 3; Ar es un grupo heteroarilo de seis miembros. Los presentes compuestos son como moduladores de gamma-secretasa para el tratamiento de enfermedades asociadas al deposito de beta-amiloide en el cerebro, tales como enfermedad de Alzheimer, hipoacusia, demencia multiinfarto, demencia pugilistica y sindrome de Down. Un compuesto de ejemplo es (R)-7-(3,5-difluorofenoxi)-N- ((1R,5S,8s)-3-(6-metoxipiridazin-4-il)-3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5Hpirrolo[1,2-b][1,2,4]triazol-2-amina.
PE2021000726A 2018-12-13 2019-12-11 Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer PE20211776A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212199 2018-12-13
PCT/EP2019/084538 WO2020120521A1 (en) 2018-12-13 2019-12-11 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
PE20211776A1 true PE20211776A1 (es) 2021-09-08

Family

ID=64665266

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000726A PE20211776A1 (es) 2018-12-13 2019-12-11 Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer

Country Status (19)

Country Link
US (1) US20220056036A1 (es)
EP (1) EP3894411A1 (es)
JP (1) JP2022513466A (es)
KR (1) KR20210102900A (es)
CN (2) CN117946116A (es)
AR (1) AR116906A1 (es)
AU (1) AU2019395774A1 (es)
BR (1) BR112021009443A2 (es)
CA (1) CA3117870A1 (es)
CL (1) CL2021001547A1 (es)
CO (1) CO2021006837A2 (es)
CR (1) CR20210305A (es)
IL (2) IL310081A (es)
MA (1) MA54447A (es)
MX (1) MX2021006761A (es)
PE (1) PE20211776A1 (es)
SG (1) SG11202103340PA (es)
TW (1) TWI831892B (es)
WO (1) WO2020120521A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP3347363B1 (en) * 2015-09-09 2020-01-01 H. Hoffnabb-La Roche Ag N-(3-azabicyclo[3.2.1]octan-8-yl)-8-(4-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[l,5-a]pyridin-2-amine derivatives as gamma-secretase modulators for treating alzheimer's disease
CN108137579B (zh) * 2015-12-10 2022-01-07 豪夫迈·罗氏有限公司 桥连哌啶衍生物
EP3475279B1 (en) * 2016-06-27 2021-07-14 F. Hoffmann-La Roche AG Triazolopyridines as gamma-secretase modulators
CN109641912B (zh) * 2016-11-01 2021-10-29 豪夫迈·罗氏有限公司 二环杂芳基衍生物
US11319314B2 (en) * 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy

Also Published As

Publication number Publication date
EP3894411A1 (en) 2021-10-20
AR116906A1 (es) 2021-06-23
CR20210305A (es) 2021-07-20
MA54447A (fr) 2022-03-23
CL2021001547A1 (es) 2021-12-24
IL283823B1 (en) 2024-03-01
JP2022513466A (ja) 2022-02-08
SG11202103340PA (en) 2021-04-29
CA3117870A1 (en) 2020-06-18
IL283823A (en) 2021-07-29
KR20210102900A (ko) 2021-08-20
WO2020120521A1 (en) 2020-06-18
CN113179641A (zh) 2021-07-27
CO2021006837A2 (es) 2021-06-10
IL310081A (en) 2024-03-01
MX2021006761A (es) 2021-07-15
BR112021009443A2 (pt) 2021-08-17
AU2019395774A1 (en) 2021-04-08
TWI831892B (zh) 2024-02-11
US20220056036A1 (en) 2022-02-24
CN117946116A (zh) 2024-04-30
TW202039499A (zh) 2020-11-01
CN113179641B (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
PH12015501878A1 (en) Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
LT3625233T (lt) 3-(((((2s,5r)-2-karbamoil-7-okso-1,6-diazabiciklo[3.2.1]oktan-6-il)oksi) sulfonil)oksi)-2,2-dimetilpropanoato dariniai ir susiję junginiai kaip peroraliniu būdu įvedami provaistai – beta-laktamazės inhibitoriai, skirti bakterinių infekcijų gydymui
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
NZ628969A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
PH12016501481A1 (en) Ethynyl derivatives
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
PE20190778A1 (es) Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
MX2017005715A (es) Potentes moduladores de gamma-secretasa.
PE20211776A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
PE20221454A1 (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4
MX2013014662A (es) Derivados de sulfonamida de aminas aliciclicas para el tratamiento de enfermedades del sistema nervioso central.
PE20150341A1 (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona
AR121666A1 (es) DERIVADOS DE NAFTIRIDINA Y PIRIDO[3,4-C]PIRIDAZINA COMO MODULADORES DEL RECEPTOR GABAA a5
MX2021011026A (es) Forma cristalina de un derivado de avibactam.
AR100532A1 (es) Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona